The US FDA has granted accelerated approval to XPOVIO for the treatment of resistant or relapsed multiple myeloma. XPOVIO (Selinexor) was developed by Karyopharm Therapeutics, established by Israel’s Dr. Sharon Shacham,.and based in Newton MA.

https://www.jpost.com/HEALTH-SCIENCE/Israeli-made-innovative-cancer-treatment-gets-FDA-stamp-of-approval-600505

https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-announces-fda-approval-xpoviotm-selinexor-treatment

https://www.youtube.com/watch?v=D1NW1Tq57YU